Despite progress with statins, cardiovascular disease remains the leading global killer. New LDL-, triglyceride-, and Lp(a)-targeting treatments—including oral PCSK9 inhibitors and gene-editing approaches—are advancing through
A recent Washington Post article underscores the growing importance of lipoprotein(a), or Lp(a)—a genetically-driven lipid that significantly raises the risk of heart attack and stroke—even
Data from the ALPACA Phase II trial reveal that lepodisiran, an siRNA therapy, reduced Lp(a) levels by nearly 94% up to six months with a
A major JACC-based study finds that measuring troponin—even within normal ranges—can significantly improve prediction of heart attack or stroke risk, especially among individuals considered at
Ortus is committed to transforming critical care through premium-quality ICU and hospital equipment. With a reputation built on trust, innovation, and service excellence, we empower healthcare providers with the tools they need to save lives.